Grigori Joffe

Summary

Affiliation: Helsinki University Central Hospital
Country: Finland

Publications

  1. ncbi Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial
    Grigori Joffe
    Kellokoski Hospital, Kellokoski, Finland
    J Clin Psychiatry 69:706-11. 2008
  2. ncbi Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: a prospective, randomized study
    Grigori Joffe
    Department of Psychiatry, Helsinki University Central Hospital, Välskärinkatu 12, Helsinki, Finland
    Int J Technol Assess Health Care 24:399-402. 2008
  3. ncbi Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial
    Grigori Joffe
    Department of Psychiatry, Helsinki Univercity Central Hospital HUCH, Helsinki, Finland
    Schizophr Res 108:245-51. 2009
  4. ncbi Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial
    Evgueni Tchoukhine
    Helsinki University Central Hospital, Peijas Hospital, 01400 Vantaa, Helsinki, Finland
    J Clin Psychiatry 72:326-30. 2011
  5. ncbi More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia
    Jan Henry Stenberg
    Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland
    Prog Neuropsychopharmacol Biol Psychiatry 35:1080-6. 2011
  6. ncbi More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial
    Viacheslav Terevnikov
    Kellokoski Hospital, Kellokoski, Finland
    Hum Psychopharmacol 25:431-8. 2010
  7. ncbi Add‐on mirtazapine improves depressive symptoms in schizophrenia: a double‐blind randomized placebo‐controlled study with an open‐label extension phase
    Viacheslav Terevnikov
    Kellokoski Hospital, Kellokoski, Finland
    Hum Psychopharmacol 26:188-93. 2011
  8. ncbi Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study
    Jan Henry Stenberg
    Department of Psychiatry, Helsinki University Central Hospital HUCH, Helsinki, Finland
    Int J Neuropsychopharmacol 13:433-41. 2010
  9. ncbi Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation
    Jan Henry Stenberg
    Helsinki University Central Hospital HUCH, Helsinki, PO Box 750, FI 00029 Huch, Finland
    Neuropharmacology 64:248-53. 2013
  10. ncbi Seclusion and restraint in psychiatry: patients' experiences and practical suggestions on how to improve practices and use alternatives
    Raija Kontio
    Department of Psychiatry, University of Turku, Department of Nursing Science, Turku, Finland
    Perspect Psychiatr Care 48:16-24. 2012

Collaborators

Detail Information

Publications17

  1. ncbi Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial
    Grigori Joffe
    Kellokoski Hospital, Kellokoski, Finland
    J Clin Psychiatry 69:706-11. 2008
    ..We investigated the feasibility of treatment with orlistat, a weight-control drug with no central effects, for overweight/obesity in clozapine- or olanzapine-treated male and female patients...
  2. ncbi Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: a prospective, randomized study
    Grigori Joffe
    Department of Psychiatry, Helsinki University Central Hospital, Välskärinkatu 12, Helsinki, Finland
    Int J Technol Assess Health Care 24:399-402. 2008
    ..The aim of this study was to elucidate, whether shift from first generation antipsychotics (FGA) to olanzapine can affect health-related quality of life (HRQoL) of residually symptomatic schizophrenic outpatients...
  3. ncbi Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial
    Grigori Joffe
    Department of Psychiatry, Helsinki Univercity Central Hospital HUCH, Helsinki, Finland
    Schizophr Res 108:245-51. 2009
    ..We explored the efficacy of adjunctive mirtazapine on symptoms of schizophrenia in patients having an insufficient response to different FGAs...
  4. ncbi Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial
    Evgueni Tchoukhine
    Helsinki University Central Hospital, Peijas Hospital, 01400 Vantaa, Helsinki, Finland
    J Clin Psychiatry 72:326-30. 2011
    ..To explore long-term effects of orlistat in adult clozapine- or olanzapine-treated patients with DSM-IV-diagnosed schizophrenia and overweight or obesity who tolerate orlistat...
  5. ncbi More evidence on proneurocognitive effects of add-on mirtazapine in schizophrenia
    Jan Henry Stenberg
    Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland
    Prog Neuropsychopharmacol Biol Psychiatry 35:1080-6. 2011
    ..Lengthy treatment seems worthwhile. Mirtazapine may become a safe and cost-saving neurocognitive enhancer in schizophrenia, yet more studies are needed...
  6. ncbi More evidence on additive antipsychotic effect of adjunctive mirtazapine in schizophrenia: an extension phase of a randomized controlled trial
    Viacheslav Terevnikov
    Kellokoski Hospital, Kellokoski, Finland
    Hum Psychopharmacol 25:431-8. 2010
    ..The short duration of that trial was its limitation. This study aimed to explore whether longer treatment is worthwhile...
  7. ncbi Add‐on mirtazapine improves depressive symptoms in schizophrenia: a double‐blind randomized placebo‐controlled study with an open‐label extension phase
    Viacheslav Terevnikov
    Kellokoski Hospital, Kellokoski, Finland
    Hum Psychopharmacol 26:188-93. 2011
    ..Depressed patients with schizophrenia may benefit from mirtazapine–first‐generation antipsychotics combination, with no increased risk for psychosis. However, more studies are needed...
  8. ncbi Effects of add-on mirtazapine on neurocognition in schizophrenia: a double-blind, randomized, placebo-controlled study
    Jan Henry Stenberg
    Department of Psychiatry, Helsinki University Central Hospital HUCH, Helsinki, Finland
    Int J Neuropsychopharmacol 13:433-41. 2010
    ..Larger and longer studies that incorporate functional outcomes, as well as comparisons with second-generation antipsychotics are, however, still needed for more definite conclusions...
  9. ncbi Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation
    Jan Henry Stenberg
    Helsinki University Central Hospital HUCH, Helsinki, PO Box 750, FI 00029 Huch, Finland
    Neuropharmacology 64:248-53. 2013
    ..Path analysis may be a feasible statistical method for further research of neurocognition in psychopharmacological interventions in schizophrenia. This article is part of a Special Issue entitled 'Cognitive Enhancers'...
  10. ncbi Seclusion and restraint in psychiatry: patients' experiences and practical suggestions on how to improve practices and use alternatives
    Raija Kontio
    Department of Psychiatry, University of Turku, Department of Nursing Science, Turku, Finland
    Perspect Psychiatr Care 48:16-24. 2012
    ..This study explored psychiatric inpatients' experiences of, and their suggestions for, improvement of seclusion/restraint, and alternatives to their use in Finland...
  11. ncbi Nurses' and physicians' educational needs in seclusion and restraint practices
    Raija Kontio
    University of Turku, Department of Nursing Science, Turku, Finland
    Perspect Psychiatr Care 45:198-207. 2009
    ..This study aimed to explore nurses' (N= 22) and physicians' (N= 5) educational needs in the context of their perceived seclusion and restraint-related mode of action and need for support...
  12. ncbi Decreased production of reactive oxygen species by blood monocytes caused by clozapine correlates with EEG slowing in schizophrenic patients
    Andres Gross
    Helsinki University Psychiatry Clinic, Tammisaari, Finland
    Neuropsychobiology 47:73-7. 2003
    ..However, this proposition has to be confirmed by future research...
  13. ncbi Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine
    Bjorn Appelberg
    Department of Psychiatry, Helsinki University Central Hospital, POB 590, 00029 HUS, Finland
    Eur Psychiatry 19:516-8. 2004
    ..After 12 weeks patients on olanzapine exhibited significant improvement in neurological side effects and psychotic symptomatology as compared to patients on conventional antipsychotics...
  14. ncbi Secluded/restrained patients' perceptions of their treatment: validity and reliability of a new questionnaire
    Toshie Noda
    Department of Social Psychiatry, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan
    Psychiatry Clin Neurosci 66:397-404. 2012
    ..To develop a standardized self-reporting questionnaire to evaluate patients' perceptions of their overall treatment in specific relation to the use of seclusion and/or restraint (SR) measures as part of the treatment program...
  15. ncbi Patient restrictions: are there ethical alternatives to seclusion and restraint?
    Raija Kontio
    University of Turku, Turku, Finland, and Kellokoski Hospital, Tuusula, Finland
    Nurs Ethics 17:65-76. 2010
    ....
  16. ncbi Altered expression of myeloperoxidase precursor, myeloid cell nuclear differentiation antigen, Fms-related tyrosine kinase 3 ligand, and antigen CD11A genes in leukocytes of clozapine-treated schizophrenic patients
    Liisa Lahdelma
    J Clin Psychopharmacol 26:335-8. 2006
  17. ncbi Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial
    Jari Tiihonen
    Department of Forensic Psychiatry, University of Kuopio, Niuvanniemi Hospital, Kuopio, Finland
    J Clin Psychiatry 66:1012-5. 2005
    ..We tested the hypothesis that topiramate is more effective than placebo in reducing symptoms in patients with treatment-resistant schizophrenia when combined with ongoing antipsychotic medication...